The cellular mechanism of glucocorticoid acceleration of fetal lung maturation. Fibroblast-pneumonocyte factor stimulates choline-phosphate cytidylyltransferase activity.
The cellular mechanism by which glucocorticoids stimulate phosphatidylcholine biosynthesis has been studied in the fetal rat lung in vivo and in cultured fetal rat lung cells of varying levels of complexity. Administration of dexamethasone to pregnant rats at 18 days gestation resulted in a significant increase in saturated phosphatidylcholine content in fetal lung 24 h after injection. Dexamethasone administration increased the activity of fetal lung choline-phosphate cytidylyltransferase by 34%. It had no effect on the activities of fetal lung choline kinase and choline phosphotransferase. Exposure of fetal lung type II cells in organotypic cultures (which contain both type II cells and fibroblasts) to cortisol resulted in a 1.6-fold increase in the incorporation of [Me-3H]choline into saturated phosphatidylcholine. The activities of the enzymes in the choline pathway for the de novo biosynthesis of phosphatidylcholine were not significantly altered except for a 105% increase in choline-phosphate cytidylyltransferase activity. Treatment of monolayer cultures of fetal type II cells with cortisol-conditioned medium from fetal lung fibroblasts resulted in a 1.5-fold increase in saturated phosphatidylcholine production. This effect correlated with a doubling of choline-phosphate cytidylyltransferase activity. Additional evidence that this stimulatory action is mediated by fibroblast-pneumonocyte factor, produced by fetal lung fibroblasts in response to cortisol, was obtained. The factor was partially purified from cortisol-conditioned medium of fetal lung fibroblasts by gel filtration and affinity chromatography. Based on biological activity, a 3000-fold purification was obtained. Stimulation of saturated phosphatidylcholine synthesis in type II cells by fibroblast-pneumonocyte factor was maximal within 60 min of incubation. Pulse-chase experiments indicated that the stimulatory effect was correlated with an increased conversion of choline phosphate into CDP choline. Moreover, the enhanced phosphatidylcholine formation by fetal type II cells in response to fibroblast-pneumonocyte factor was accompanied by decreased levels of cellular choline phosphate. These findings further support the concept that glucocorticoid action on surfactant-associated phosphatidylcholine synthesis occurs ultimately at the level of the alveolar type II cell and involves fibroblast-pneumonocyte factor which stimulates the activity of choline-phosphate cytidylyltransferase.
D000818:Animals; D002478:Cells, Cultured; D002797:Choline Kinase / Q000032:analysis; D019916:Choline-Phosphate Cytidylyltransferase; D003907:Dexamethasone / Q000494:pharmacology*; D002798:Diacylglycerol Cholinephosphotransferase / Q000032:analysis; D005260:Female; D005325:Fetal Organ Maturity / Q000187:drug effects; D005346:Fibroblast Growth Factors / Q000302:isolation & purification / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects; D006854:Hydrocortisone / Q000494:pharmacology*; D008168:Lung / Q000032:analysis / Q000187:drug effects / Q000196:embryology*; D009713:Nucleotidyltransferases / Q000032:analysis; D010713:Phosphatidylcholines / Q000032:analysis; D011247:Pregnancy; D011663:Pulmonary Surfactants / Q000096:biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains; D013268:Stimulation, Chemical
D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants; C044220:fibroblast pneumonocyte factor; D005346:Fibroblast Growth Factors; D003907:Dexamethasone; D002797:Choline Kinase; D009713:Nucleotidyltransferases; D019916:Choline-Phosphate Cytidylyltransferase; D002798:Diacylglycerol Cholinephosphotransferase; D006854:Hydrocortisone